# Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

> **NCT02029378** · PHASE2 · UNKNOWN · sponsor: **NHS Greater Glasgow and Clyde** · enrollment: 30 (estimated)

## Conditions studied

- Gullian Barre Syndrome

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT02029378
- **Lead sponsor:** NHS Greater Glasgow and Clyde
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2015-10
- **Final completion:** 2016-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029378, "Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02029378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*